Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

EB2023 primes mitochondria for BCL2 dependence and induces pyroptotic cell death via AMPK signaling and the unfolded protein response

View Full Paper
Ask AI
Bookmark
Share

Authors

MDMichael DavidsonSCSovira ChaudhryBRBenjamin Reisman

Discussion

Loading...

Member takes

Overview

Analysis reveals EB2023 promotes pyroptotic cell death in AML, suggesting synergy with BCL2 inhibitors for enhanced anti-cancer activity.

Key Points

  • EB2023 induces pyroptotic cell death in AML cells, emphasizing its potential as an anti-cancer agent.
  • The compound displayed IC50 values ranging from 5-91 nM across cancer cell lines, confirming broad activity.
  • Assessment using RNA-sequencing and gene set enrichment analysis highlighted significant activation of pyroptosis and unfolded protein response pathways.
  • These findings indicate a promising combination strategy with BCL2 inhibitors like venetoclax to enhance treatment efficacy in AML.

Cite This Study

Davidson et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d442https://doi.org/10.1182/blood-2025-637
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1LSD1 inhibition enhances venetoclax efficacy in Acute Myeloid Leukemia via metabolic rewiring2025
  2. 2F1 subunit-specific ATP synthase inhibition disrupts AML mitochondrial metabolism distinctly from other electron transport chain inhibitors2025 · 1 citations
  3. 3Amx-883, a potent and selective degrader of BRD9 drives differentiation in acute myeloid leukaemia and shows synergistic efficacy in combination with venetoclax In Vivo and prevents the emergence of resistance to venetoclax in vitro.2025 · 1 citations
  4. 4A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available clk inhibitor, BH-30236, in adults with R/R AML or HR-MDS2025
  5. 5Synergistic antitumor effects and mechanisms of KPT-330 combined with venetoclax in Acute Myeloid Leukemia2025